Holen Sie sich die Stockscreener-App
3.78
0.53%
0.02
Handel nachbörslich:
3.78
Schlusskurs vom Vortag:
$3.76
Offen:
$3.87
24-Stunden-Volumen:
72,516
Relative Volume:
1.76
Marktkapitalisierung:
$16.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.61M
KGV:
-4.20
EPS:
-0.9
Netto-Cashflow:
$-22.91M
1W Leistung:
+1.07%
1M Leistung:
-0.26%
6M Leistung:
+27.70%
1J Leistung:
+605.09%
1-Tages-Spanne:
$3.57
$4.25
1-Wochen-Bereich:
$3.55
$4.25
52-Wochen-Spanne:
$0.0815
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Firmenname
Bioline Rx Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.78 | 16.03M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-05-18 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-02-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-12 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-08-17 | Bestätigt | Maxim Group | Buy |
| 2015-07-27 | Bestätigt | ROTH Capital | Buy |
| 2015-06-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Bioline Rx Ltd Adr Aktie (BLRX) Neueste Nachrichten
BioLineRx, Hemispherian AS establish joint venture to develop GLIX1 - TipRanks
BioLineRx and Hemispherian form joint venture to develop brain cancer drug - Investing.com
BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma - TipRanks
BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
BioLineRx ADR Earnings Call: Optimism Amid Challenges - MSN
Earnings call transcript: BioLineRx Q2 2025 sees restructuring and innovation - Investing.com
BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating - TipRanks
BioLineRx Ltd. Reports Q2 2025 Financial Results - TipRanks
BioLineRx Reports Q2 2025 Financials and Strategic Updates - MSN
BioLineRx To Report Second Quarter 2025 Results On August 14, 2025 - Barchart.com
BioLineRx: Promising Financial Position and Strategic Initiatives Drive Buy Rating - TipRanks
BioLineRx Reports Second Quarter 2025 Financial Results And Provides Corporate Update - Barchart.com
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
BioLineRx Ltd. Approves Key Proposals at Annual Meeting - TipRanks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com South Africa
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India
BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks
Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com South Africa
Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com India
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks
BioLineRx reports promising pancreatic cancer trial data - Investing.com
JonesTrading Reaffirms Their Hold Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects - Investing.com India
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock By Investing.com - Investing.com South Africa
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks
BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks
BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Analysts’ Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), Fulcrum Therapeutics (FULC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail
Finanzdaten der Bioline Rx Ltd Adr-Aktie (BLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):